Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Growth Hormone
Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation.
Peptide B
Muscle Growth
Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling.
Typical vial
2 mg
Typical dose
100-300 mcg
Half-life
~30 minutes (no DAC) / 6-8 days (with DAC)
FDA status
Not FDA approved for human use.
Typical vial
1 mg
Typical dose
20-50 mcg
Half-life
~20-30 hours
FDA status
Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Inc…
CJC-1295 effects
IGF-1 LR3 effects
CJC-1295 side effects
IGF-1 LR3 side effects
CJC-1295 dosing ranges
Anti-aging and recovery (Mod GRF)
100 mcg · Once to three times daily (SubQ) · 8-12 weeks
Body composition (Mod GRF + Ipamorelin)
100-300 mcg · Two to three times daily · 8-12 weeks
CJC-1295 with DAC
1000-2000 mcg · Once or twice weekly · 8-12 weeks
IGF-1 LR3 dosing ranges
Research / muscle hypertrophy
20-50 mcg · Once daily (SubQ or IM), pre- or post-workout · 30-50 days per cycle
Site-specific injection (research)
20-40 mcg per site · Into trained muscle, post-workout · 30-50 days per cycle
CJC-1295: Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation. Typical dose 100-300 mcg. IGF-1 LR3: Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling. Typical dose 20-50 mcg. Both fall under the Growth Hormone and Muscle Growth categories.
Stacking CJC-1295 with IGF-1 LR3 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
CJC-1295 is typically dosed: Once to three times daily (SubQ) for Anti-aging and recovery (Mod GRF); Two to three times daily for Body composition (Mod GRF + Ipamorelin); Once or twice weekly for CJC-1295 with DAC. IGF-1 LR3 is typically dosed: Once daily (SubQ or IM), pre- or post-workout for Research / muscle hypertrophy; Into trained muscle, post-workout for Site-specific injection (research).
CJC-1295: Not FDA approved for human use. IGF-1 LR3: Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Increlex) is FDA approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 itself is not.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free